@article{TAU30380,
author = {Denzel Zhu and Emily Barry and Alexander I. Sankin},
title = {Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway},
journal = {Translational Andrology and Urology},
volume = {8},
number = {Suppl 5},
year = {2019},
keywords = {},
abstract = {Bladder cancer (BCa) is the fourth most common malignancy among men, and is the eighth most common cause of cancer death in the US (1). Once muscle-invasive, the treatment options for BCa are limited, and include radical cystectomy with or without neoadjuvant platinum-based chemotherapy or organ sparing chemoradiotherapy (2). In 2016, the treatment of metastatic BCa (mBCa) was revolutionized by results of a phase II trial of immune checkpoint programmed death-ligand 1 (PD-L1) inhibitor atezolizumab in 311 patients with mBCa who progressed after chemotherapy (3,4). The trial found a response rate of 15% in patients receiving 1,200 mg atezolizumab for 3 weeks, which was a significant improvement over systemic chemotherapy historical controls, which had a response rate of 10% (2). Several additional trials of other inhibitors of the PD-1/PD-L1 pathway in mBCa, such as pembrolizumab (5), nivolumab (6), durvalumab (7), and avelumab (8), also found sustained response in mBCa patients.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/30380}
}